等待开盘 12-19 09:30:00 美东时间
-1.460
-26.74%
Biodexa Announces Pricing of $10 Million Public OfferingBiodexa Pharmaceuticals PLC, (NASDAQ:BDRX) ("Biodexa" or the "Company"), a clinical stage biopharmaceutical company developing a pipeline of innovative products for
12-18 21:40
Biodexa Pharmaceuticals PLC, (NASDAQ:BDRX) ("Biodexa" or the "Company"), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs,
12-18 21:38
Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) shares moved upwards by 38.7% to...
12-16 20:05
Shares of B Riley Financial Inc (NASDAQ:RILY) rose sharply in pre-market tradin...
12-16 18:53
Shares of Mama’s Creations Inc (NASDAQ:MAMA) rose sharply in pre-market trading...
12-09 17:48
Gainers Olema Pharmaceuticals (NASDAQ:OLMA) stock increased by 137.7% to $20.2...
11-19 01:06
Biodexa shares are trading higher after the company announced that the European...
11-03 21:38
Gainers Bluejay Diagnostics (NASDAQ:BJDX) shares rose 113.4% to $3.99 during T...
10-09 20:07
Biodexa Pharmaceuticals PLC will host a breakfast symposium on FAP mechanisms and chemoprevention trial issues at the CGA-IGC conference on October 11, 2025, in St. Louis, MO. Featuring guest speaker Dr. Patrick Lynch and a panel discussion with Drs. Sonia Kupfer and Paul Wise, the event aims to advance FAP treatment options and support Biodexa's Phase 3 Serenta trial for eRapa. Biodexa is focused on developing innovative therapies for unmet medi...
10-06 12:30
https://www.sec.gov/Archives/edgar/data/1643918/000121465925014255/b923250f3.htm
09-27 05:04